切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2017, Vol. 11 ›› Issue (15) : 2097 -2100. doi: 10.3877/cma.j.issn.1674-0785.2017.15.008

所属专题: 文献

综述

米氮平在精神药物不良反应中的应用进展
于相芬1, 孙宇新2, 孙振晓1,()   
  1. 1. 276005 临沂市精神卫生中心精神科
    2. 250012 济南,山东大学医学院2013级
  • 收稿日期:2017-02-16 出版日期:2017-08-01
  • 通信作者: 孙振晓

Application of mirtazapine in management of side effects of psychotropic drugs

Xiangfen Yu1, Yuxin Sun2, Zhenxiao Sun1,()   

  1. 1. Department of Psychiatry, Linyi Municipal Mental Health Center, Linyi 276005, China
    2. 2013 Grade of Medical College of Shandong University, Jinan 250012, China
  • Received:2017-02-16 Published:2017-08-01
  • Corresponding author: Zhenxiao Sun
  • About author:
    Corresponding author: Sun Zhenxiao, Email:
引用本文:

于相芬, 孙宇新, 孙振晓. 米氮平在精神药物不良反应中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2017, 11(15): 2097-2100.

Xiangfen Yu, Yuxin Sun, Zhenxiao Sun. Application of mirtazapine in management of side effects of psychotropic drugs[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(15): 2097-2100.

米氮平(Mirtazapine)是一种去甲肾上腺素(NE)和特异性5-羟色胺(5-HT)能抗抑郁剂,近年来,被应用于多种精神药物不良反应的治疗。本文对米氮平在抗精神病药物所致静坐不能、选择性5-HT再摄取抑制剂所致抗利尿激素不适当分泌综合征、多汗症、恶心、呕吐、尿潴留、帕罗西汀所致高催乳素血症乳溢、精神药物所致性功能障碍、氯氮平所致流涎、协助苯二氮类药物戒断中的应用情况作一综述。

Mirtazapine is a noradrenergic and specific serotonergic antidepressant, and it has been used to manage the side effects of many psychotropic drugs. This paper reviews the application of mirtazapine in the management of antipsychotic-induced akathisia, selective serotonin reuptake inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone, hyperhidrosis, nausea, vomiting, urinary retention, paroxetine-induced hyper-prolactinemic galactorrhoea, psychotropic drug-induced sexual dysfunction, and clozapine-induced sialorrhea, as well as in aiding benzodiazepine withdrawal.

[1]
孙振晓,于相芬,孙波. 米氮平的临床应用及其不良反应 [J]. 精神医学杂志, 2012, 25(4):310-313.
[2]
Poyurovsky M, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem [J]. Br J Psychiatry, 2001, 179(1):4-8.
[3]
于相芬,孙振晓,孙波. 抗精神病药物所致急性静坐不能的研究现状 [J]. 中国执业药师, 2012, 9(4):32-38.
[4]
Poyurovsky M. Acute antipsychotic-induced akathisia revisited [J]. Br J Psychaitry, 2010, 196(2):89-91.
[5]
Poyurovsky M, Weizman A. Mirtazapine for neuroleptic-induced akathisia [J]. Am J Psychiatry, 2001, 158(5):819.
[6]
Poyurovsky M, Bergman J, Pashinian A, et al. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia [J]. Int Clin Psychopharmacol, 2014, 29(5):296-298.
[7]
Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia [J]. Ann Pharmacother, 2008, 42(6):841-846.
[8]
Praharaj SK, Kongasseri S, Behere RV, et al. Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials [J]. Ther Adv Psychopharmacol, 2015, 5(5):307-313.
[9]
Koufakis T. Quetiapine-induced syndrome of inappropriate secretion of antidiuretic hormone [J]. Case Rep Psychiatry, 2016, 2016:4803132.
[10]
Jagsch C, Marksteiner J, Seiringer E, et al. Successful mirtazapine treatment of an 81-year-old patient with syndrome of inappropriate antidiuretic hormone secretion [J]. Pharmacopsychiatry, 2007, 40(3):129-131.
[11]
Mogi T, Yoshino A, Ikemoto G, et al. Mirtazapine as an alternative for selective-serotonin-reuptake-inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone [J]. Psychiatry Clin Neurosci, 2012, 66(1):80.
[12]
孙振晓,于相芬. 抗抑郁剂所致多汗症的研究现状 [J]. 中国执业药师, 2013, 10(12):23-25, 38.
[13]
Buecking A, Vandeleur CL, Khazaal Y, et al. Mirtazapine in drug-induced excessive sweating [J]. Eur J Clin Pharmacol, 2005, 61(7):543-544.
[14]
Edwards JG, Anderson I. Systematic review and guide to selelection of selective serotonin reuptake inhibitors [J]. Drugs, 1999, 57(4):507-533.
[15]
Caldis EV, Gair RD. Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors [J]. Can J Psychiatry, 2004, 49(10):707.
[16]
喻东山,葛茂宏,苏海陵. 精神科合理用药手册[M]. 3版. 南京: 江苏凤凰科学技术出版社, 2016: 270.
[17]
Lenze EJ. Reversal of SSRI-associated urinary retention with mirtazapine augmentation [J]. J Clin Psychopharmacol, 2012, 32(3):434.
[18]
Chatterjee SS, Mitra S, Mallik N. Emerging hyperprolactinemic galactorrhea in obsessive compulsive disorder with a stable dose of Fluoxetine [J]. Clin Psychopharmacol Neurosci, 2015, 13(3):316-318.
[19]
Stahl S. Stahl′s essential psychopharmacology: neuroscientific basis and practical application [M]. 4th ed. Cambridge: Cambridge University Press, 2013: 298-318.
[20]
Singh M, Anwar Z, Sinha V, et al. Mirtazapine in Paroxetine Induced Hyper-prolactinemic Galactorrhoea [J]. Clin Psychopharmacol Neurosci, 2015, 13(2):222-223.
[21]
Fava M, Rankin M. Sexual functioning and SSRIs [J]. J Clin Psychiatry, 2002, 63(S5):25-30.
[22]
Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer anti- depressants [J]. J Clin Psychiatry, 2002, 63(4):357-366.
[23]
Khawam EA, Laurencic G, Malone JR. Side effects of antidepressants: An overview [J]. Cleveland Clin J Med, 2006, 73(4):351-361.
[24]
Atmaca M, Korkmaz S, Topuz M, et al. Mirtazapine augmentation for selective serotonin reuptake inhibitor-induced sexual dysfunction: a retropective investigation [J]. Psychiatry Investig, 2011, 8(1):55-57.
[25]
Gelenberg AJ, McGahuey C, Laukes C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction [J]. J Clin Psychiatry, 2000, 61(5):356-360.
[26]
Ozmenler NK, Karlidere T, Bozkurt A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors [J]. Hum Psychopharmacol, 2008, 23(4):321-326.
[27]
Terevnikov V, Stenberg JH, Tiihonen J, et al. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics [J]. Nord J Psychiatry, 2017, 71(1):77-80.
[28]
Glick AR, Khan IA, Sher L. Treatment of antipsychotic-induced sialorrhea [J]. Psychiat Ann, 2014, 44(6):267-269.
[29]
张荣华,季建林. 苯二氮卓类药物的依赖及戒断 [J]. 国外医学(精神病学分册), 2005, 32(2):82-85.
[30]
Chandrasekaran PK. Employing mirtazapine to aid benzodiazepine withdrawal [J]. Singapore Med J, 2008, 49(6):e166-167.
[1] 李雪, 韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2低表达乳腺癌的研究进展及挑战[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 308-312.
[2] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[3] 何羽. 腔镜微创手术治疗分化型甲状腺癌的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 456-458.
[4] 赵淑樱, 张聃. 腹腔镜胃癌外科治疗进展与发展趋势[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 459-462.
[5] 刘璐璐, 何羽. 慢性阻塞性肺病患者睡眠障碍的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 836-839.
[6] 张瑜, 姜梦妮. 基于DWI信号值构建局部进展期胰腺癌放化疗生存获益预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 657-664.
[7] 王哲学, 白峻阁, 姜得地, 李月刚, 杨明, 陈海鹏, 刘正. 局部进展期直肠癌经新辅助放化疗后肿瘤退缩分级及预后的影响因素分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 368-374.
[8] 白正林, 高明, 孟增东. 肩关节置换术后假体周围感染的研究进展[J/OL]. 中华肩肘外科电子杂志, 2024, 12(03): 271-276.
[9] 国文凯, 纪鹏程, 毕靖茹, 谢院生. IgA 肾病的十种治疗措施[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 327-333.
[10] 武继敏, 袁春雨, 王鲁佳, 陈伟霞, 李晓东, 马丽虹. 重复经颅磁刺激治疗脑卒中后中枢性疼痛的研究进展[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(03): 182-186.
[11] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[12] 丁洪基, 赵长江, 孙鹏飞, 王灿, 王贵珍, 李龙龙. 细胞焦亡与疾病的关系研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 682-686.
[13] 黄宏山, 陈成彩. 经淋巴管超声造影在乳腺癌前哨淋巴结诊断中的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(04): 411-414.
[14] 沈海锋, 吕方伊, 顾海华, 常志博, 陈盈, 王苹莉, 吴祖群, 邱福铭, 姚杰, 范军强. 局部进展期肺癌新辅助治疗后胸腔镜袖式肺叶切除术——浙江大学医学院附属第二医院2014—2023年56例回顾性分析[J/OL]. 中华胸部外科电子杂志, 2024, 11(03): 158-166.
[15] 王丽娜, 吕书霞, 李亚男. 脑卒中偏瘫患者健康焦虑元认知与疾病接受度、恐惧疾病进展的相关性[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 434-440.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?